WeVote
Log In

Bill

Bill

S 95

Establishes that instruction in financial education be provided to pupils in grades nine, ten, eleven or twelve

2025 Regular Session Introduced by Leroy Comrie and 1 co-sponsor

Massachusetts requires standardized, detailed marijuana product labels with lab results, batch numbers, ingredients, THC amounts, warnings, and child-safety marks.

REFERRED TO EDUCATION
0
WeVote Research Nonpartisan
Bill Summary · S 95

Summary — S. 95 (2025): “An Act relative to the labeling of marijuana”

Note: the bill metadata provided (title referencing financial education and some sponsor names) appears inconsistent with the bill text. This summary focuses on the actual bill text filed as Senate No. 95 / Senate Docket No. 2433 (filed 1/17/2025), which would amend cannabis labeling requirements in Massachusetts law (G. L. c. 94G, §4).

Main purpose

To strengthen and standardize mandatory labeling requirements for packaged marijuana and marijuana products sold under Massachusetts law by specifying minimum label content, requiring health warnings informed by best-available research, and directing periodic regulatory updates.

Where it amends law

Amends subsection (a1/2) of section 4 of chapter 94G of the Massachusetts General Laws by replacing existing clause (xxvi) with a more detailed set of labeling requirements.

Key provisions (required label elements)

The bill requires that package labels for marijuana and marijuana products include, at minimum:

  1. A commission-issued symbol or easily recognizable mark indicating the package contains marijuana or a marijuana product.
  2. A commission-issued symbol or mark indicating to children that the product is harmful to children.
  3. The name and contact information of the marijuana cultivator or product manufacturer.
  4. Results of sampling, testing, and analysis performed by a licensed independent testing laboratory.
  5. A seal certifying the marijuana meets specified testing standards.
  6. A unique batch number identifying the production batch associated with manufacturing, processing, and cultivation.
  7. A list of ingredients and possible allergens.
  8. In bold, the amount of delta‑9‑tetrahydrocannabinol (Δ9‑THC) in the package and per serving, expressed in absolute terms and as a percentage of volume.
  9. The number of servings in the package, if multiple servings exist.
  10. A use‑by date, if applicable.
  11. The following statutory consumer statement (capitalization included as shown):
    “This product has not been analyzed or approved by the FDA. There is limited information on the side effects of using this product, and there may be associated health risks. Marijuana use during pregnancy and breast‑feeding may pose potential harms. It is against the law to drive or operate machinery when under the influence of this product. KEEP THIS PRODUCT AWAY FROM CHILDREN.”
  12. Comprehensive, prominent rotating health warnings informed by best-available research on effective warnings (including tobacco and cannabis warning research). These warnings may include pictorial warnings if supported by research and must be periodically updated. Warnings must specifically include the increased risk of psychosis, schizophrenia, and suicide associated with THC-containing marijuana products—especially with early initiation or frequent use.

Who would be affected

  • Marijuana cultivators, manufacturers, processors, and retail licensees (packaging and labeling practices).
  • Licensed independent testing laboratories (results must appear on labels).
  • The Cannabis Control Commission (or commission referenced) — responsible for issuing symbols/marks and for periodic regulatory updates and implementation guidance.
  • Consumers, particularly youth and pregnant/breastfeeding persons, who would receive stronger warnings and clearer product information.
  • Packaging and labeling vendors (design/print compliance), and compliance officers in the industry.

Anticipated impacts

  • Increased regulatory compliance costs for producers and retailers (label redesign, printing, batch tracking, displaying lab test data/seals).
  • Greater consumer information and potentially improved public health communication about risks (notably mental-health risks).
  • Operational changes for testing and traceability to provide lab results and batch identifiers on packaging.
  • Regulatory work for the commission to develop and issue symbols, warning standards, seal criteria, and to update warnings as science evolves.

Procedural / timeline notes

  • Introduced in the Senate: 1/15/2025 (filed 1/17/2025).
  • Recorded legislative actions show referral to committees including Cannabis Policy and Education, with a hearing scheduled for 05/07/2025 (10:30 AM–1:00 PM, B‑1).
  • The bill text does not specify an effective date, enforcement mechanisms, or penalties for noncompliance; those details would typically be addressed in implementing regulations or later bill sections not included here.

Additional context

  • The bill references adopting warning design best practices from tobacco and cannabis research and requires periodic updates as scientific understanding evolves.
  • The text specifically mandates disclosure of certain mental‑health risks tied to THC use (psychosis, schizophrenia, suicide), a notable public‑health emphasis compared to typical ingredient/nutrition-style labeling requirements.

If you would like, I can:
- Produce suggested regulatory language implementing each numbered requirement;
- Estimate compliance cost ranges for producers/retailers; or
- Draft a concise one-page fact sheet for consumers summarizing the new label elements.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.